166 related articles for article (PubMed ID: 11427209)
1. Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells.
Funatsu T; Suzuki K; Goto M; Arai Y; Kakuta H; Tanaka H; Yasuda S; Ida M; Nishijima S; Miyata K
Atherosclerosis; 2001 Jul; 157(1):107-15. PubMed ID: 11427209
[TBL] [Abstract][Full Text] [Related]
2. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin.
Wilcox LJ; Barrett PH; Huff MW
J Lipid Res; 1999 Jun; 40(6):1078-89. PubMed ID: 10357840
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231
[TBL] [Abstract][Full Text] [Related]
4. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells.
Mohammadi A; Macri J; Newton R; Romain T; Dulay D; Adeli K
Arterioscler Thromb Vasc Biol; 1998 May; 18(5):783-93. PubMed ID: 9598838
[TBL] [Abstract][Full Text] [Related]
5. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
Krause BR; Newton RS
Atherosclerosis; 1995 Oct; 117(2):237-44. PubMed ID: 8801869
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: comparison with an MTP inhibitor.
Funatsu T; Kakuta H; Takasu T; Miyata K
Eur J Pharmacol; 2002 Nov; 455(2-3):161-7. PubMed ID: 12445582
[TBL] [Abstract][Full Text] [Related]
7. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
Conde K; Pineda G; Newton RS; Fernandez ML
Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
[TBL] [Abstract][Full Text] [Related]
8. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
Roglans N; Verd JC; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
Lipids; 2002 May; 37(5):445-54. PubMed ID: 12056585
[TBL] [Abstract][Full Text] [Related]
9. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
[TBL] [Abstract][Full Text] [Related]
10. Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells.
Scharnagl H; Schinker R; Gierens H; Nauck M; Wieland H; März W
Biochem Pharmacol; 2001 Dec; 62(11):1545-55. PubMed ID: 11728391
[TBL] [Abstract][Full Text] [Related]
11. Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes.
Isusi E; Aspichueta P; Liza M; Hernández ML; Díaz C; Hernández G; Martínez MJ; Ochoa B
Atherosclerosis; 2000 Dec; 153(2):283-94. PubMed ID: 11164417
[TBL] [Abstract][Full Text] [Related]
12. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
Alaupovic P; Heinonen T; Shurzinske L; Black DM
Atherosclerosis; 1997 Aug; 133(1):123-33. PubMed ID: 9258416
[TBL] [Abstract][Full Text] [Related]
13. Reduction in hepatic non-esterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats.
Funatsu T; Goto M; Kakuta H; Suzuki M; Ida M; Nishijima S; Tanaka H; Yasuda S; Miyata K
Biochim Biophys Acta; 2002 Feb; 1580(2-3):161-70. PubMed ID: 11880241
[TBL] [Abstract][Full Text] [Related]
14. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs.
Aggarwal D; West KL; Zern TL; Shrestha S; Vergara-Jimenez M; Fernandez ML
BMC Cardiovasc Disord; 2005 Sep; 5():30. PubMed ID: 16188040
[TBL] [Abstract][Full Text] [Related]
15. Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats.
Roglans N; Sanguino E; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
J Pharmacol Exp Ther; 2002 Jul; 302(1):232-9. PubMed ID: 12065722
[TBL] [Abstract][Full Text] [Related]
16. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin.
Bergstrom JD; Bostedor RG; Rew DJ; Geissler WM; Wright SD; Chao YS
Biochim Biophys Acta; 1998 Jan; 1389(3):213-21. PubMed ID: 9512650
[TBL] [Abstract][Full Text] [Related]
17. Effects of atorvastatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs.
Briand F; Magot T; Krempf M; Nguyen P; Ouguerram K
Eur J Clin Invest; 2006 Apr; 36(4):224-30. PubMed ID: 16620283
[TBL] [Abstract][Full Text] [Related]
18. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.
Lea AP; McTavish D
Drugs; 1997 May; 53(5):828-47. PubMed ID: 9129869
[TBL] [Abstract][Full Text] [Related]
20. MTP gene polymorphisms and postprandial lipemia in familial combined hyperlipidemia: effects of treatment with atorvastatin.
Klop B; Verseyden C; Ribalta J; Salazar J; Masana L; Cabezas MC
Clin Investig Arterioscler; 2014; 26(2):49-57. PubMed ID: 24378322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]